4-chlorobenzohydrazide hydrochloride | 72512-58-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-chlorobenzohydrazide hydrochloride
• 英文别名: 4-chlorobenzoic acid hydrazide hydrochloride；4-Chlorobenzohydrazide;hydrochloride
• CAS: 72512-58-4
• 化学式: C₇H₇ClN₂O*ClH
• 分子量: 207.059
• InChiKey: VDNBVCHPFGRSDC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.37
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  55.1
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-chlorobenzohydrazide hydrochloride 、 2-[(3aR,5aR,5bR,7aR,9S,11aR,11bR,13aS)-9-acetyloxy-5a,5b,8,8,11a-pentamethyl-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3H-cyclopenta[a]chrysen-3a-yl]-2-oxoacetic acid 在 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  [EN] LUPANE TRITERPENOID DERIVATIVES AND PHARMACEUTICAL USE THEREOF
  [FR] DÉRIVÉS DE TRITERPÉNOÏDES DE LUPANE ET LEUR UTILISATION PHARMACEUTIQUE

  摘要：

  本文披露了鲁班三萜衍生物及其药用，具体为公式(I)~(III)的鲁班三萜衍生物，以及包含所述鲁班三萜衍生物或其药用可接受盐的药物组合物和联合制剂，在治疗有效剂量中使用，特别是在制备治疗HIV-1/AIDS的药物中的应用。

  公开号：

  WO2013117137A1

文献信息

• MULTI-CYCLIC COMPOUNDS
  申请人：KIMURA Teiji

  公开号：US20090062529A1

  公开（公告）日：2009-03-05

  A compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar 1 represents an imidazolyl group or the like which may be substituted with a C1-6 alkyl group, Ar 2 represents a phenyl group or the like which may be substituted with a C1-6 alkoxy group, X 1 represents a double bond or the like and Het represents a triazolyl group or the like which may be substituted with a C1-6 alkyl group or the like, is effective as a therapeutic or prophylactic agent for a disease caused by Aβ.

  一种由化学式(I)表示的化合物或其药理学可接受的盐，其中Ar1代表可用C1-6烷基基团取代的咪唑基团或类似基团，Ar2代表可用C1-6烷氧基团取代的苯基团或类似基团，X1代表双键或类似基团，Het代表可用C1-6烷基基团或类似基团取代的三唑基团或类似基团，对由Aβ引起的疾病具有治疗或预防作用。
• [EN] LUPANE TRITERPENOID DERIVATIVES AND PHARMACEUTICAL USE THEREOF<br/>[FR] DÉRIVÉS DE TRITERPÉNOÏDES DE LUPANE ET LEUR UTILISATION PHARMACEUTIQUE
  申请人：JIANGXI QINGFENG PHARMACEUTICAL INC

  公开号：WO2013117137A1

  公开（公告）日：2013-08-15

  Disclosed are lupane triterpenoid derivatives and pharmaceutical use thereof, specifically lupane triterpenoid derivatives of formulae (I)~(III), a pharmaceutical composition and a combination preparation comprising said lupane triterpenoid derivatives or a pharmaceutically acceptable salt thereof in a therapeutically-effective dose, particularly the use in preparation of a medicament for the treatment of HIV-1/AIDS.

  本文披露了鲁班三萜衍生物及其药用，具体为公式(I)~(III)的鲁班三萜衍生物，以及包含所述鲁班三萜衍生物或其药用可接受盐的药物组合物和联合制剂，在治疗有效剂量中使用，特别是在制备治疗HIV-1/AIDS的药物中的应用。
• IMIDAZOYL PYRIDINE COMPOUNDS AND SALTS THEREOF
  申请人：KIMURA Teiji

  公开号：US20110065696A1

  公开（公告）日：2011-03-17

  A compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar 1 represents an imidazolyl group or the like which may be substituted with a C1-6 alkyl group, Ar 2 represents a phenyl group or the like which may be substituted with a C1-6 alkoxy group, X 1 represents a double bond or the like and Het represents a triazolyl group or the like which may be substituted with a C1-6 alkyl group or the like, is effective as a therapeutic or prophylactic agent for a disease caused by Aβ.

  化合物的化学式为(I)或其药理学上可接受的盐，其中Ar1代表咪唑基团或类似基团，该基团可能被C1-6烷基取代，Ar2代表苯基或类似基团，该基团可能被C1-6烷氧基取代，X1代表双键或类似基团，Het代表三唑基团或类似基团，该基团可能被C1-6烷基或类似基团取代，可用作治疗或预防由Aβ引起的疾病的药物。
• POLYCYCLIC COMPOUND
  申请人：Kimura Teiji

  公开号：US20110009619A1

  公开（公告）日：2011-01-13

  Disclosed is a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, which is effective as a therapeutic or prophylactic agent for a disease induced by Aβ, wherein Ar 1 represents an imidazolyl group which may be substituted with a C1-6 alkyl group, or the like; Ar 2 represents a phenyl group which may be substituted with a C1-6 alkoxy group, or the like; X 1 represents a double bond, or the like; and Het represents a triazolyl group or the like which may be substituted with a C1-6 alkyl group or the like, or the like.

  本发明涉及一种化合物，其化学式为(I)：或其药学上可接受的盐，该化合物有效地作为由Aβ引起的疾病的治疗或预防剂。其中，Ar1表示咪唑基，可以用C1-6烷基等取代；Ar2表示苯基，可以用C1-6烷氧基等取代；X1表示双键等；Het表示三唑基等，可以用C1-6烷基等取代。
• Polycyclic compound
  申请人：Eisai R&D Management Co., Ltd.

  公开号：EP2559693A1

  公开（公告）日：2013-02-20

  Disclosed is a compound represented by the formula (I-1): or a pharmacologically acceptable salt thereof, which is effective as a therapeutic or prophylactic agent for a disease induced by Aβ, wherein X1 represents -CH=CH- and Het represents a group which may be substituted with 1 to 3 substituents selected from substituents group A1 and is represented by one of the following formulas:

  本发明公开了一种由式（I-1）表示的化合物： 或其药理上可接受的盐，可有效治疗或预防由 Aβ 诱导的疾病，其中 X1 代表-CH=CH-，Het 代表可被 1 至 3 个选自取代基 A1 的取代基取代的基团，并由下式之一表示：